How long you have been taking the medicine?

Lesfat uses

Pharmacological action

Lesfat is an drug for the treatment of central action obesity. The mechanism of action is due to selective inhibition of serotonin reuptake of norepinephrine and, to a lesser extent, of dopamine. This medication accelerates the onset and prolong satiety, which leads to a decrease in food consumption. It increases energy expenditure by stimulating thermogenesis mediated by activation of beta3-adrenergic receptors. Acts on both sides of the balance of energy and helps Lesfat body weight.

Sibutramine and its metabolites did not release monoamines, and they are not MAO inhibitors, have no affinity for serotonergic, adrenergic, dopaminergic, muscarinic, histamine, benzodiazepine and NMDA receptors.


After oral administration Lesfat is rapidly absorbed from the gastrointestinal tract. Almost completely metabolized in the liver, with the participation of cytochrome isozymes CYP3A4, as well as by hydroxylation and conjugation to form inactive metabolites. Cmax of sibutramine is achieved in 1.2 h. This medicine is quickly and widely distributed in tissues. The plasma protein binding is 97%. T1/2 is 1.1 h. Lesfat derived primarily by the kidneys as inactive metabolites.

Why is Lesfat prescribed?

As part of the supporting complex treatment of patients with overweight in alimentary obesity with a body mass index of 30 kg / m2 or more, with alimentary obesity with a body mass index of 27 kg / m2 or more in the presence of other risk factors due to overweight, including diabetes mellitus type 2, or hyperlipidemia.

Dosage and administration

The initial dose is 10 mg / day. With lack of effectiveness when used in this dose (weight loss less than 2 kg for 4 weeks) and if tolerated the dose can be increased to 15 mg / day.

If no effect when Lesfat used in doses of 15 mg / day (weight loss less than 2 kg per 4 weeks), this drug should be discontinued.

In patients not adequately responding to treatment, that is who within 3 months can not reach the level of 5% weight loss from baseline, the duration of use this medication should not exceed 3 months.

The course of treatment is not more than 1 year since no data on efficacy and safety of longer use.

Do not use sibutramine, if after made weight loss achieved in the course of further therapy, the patient again adds to the weight of 3 kg or more.


Lesfat side effects, adverse reactions

Digestive system: frequently - anorexia, constipation, dry mouth, nausea, transient increases in liver enzymes.

CNS and peripheral nervous system: insomnia, headaches, dizziness, anxiety, paresthesia, increased sweating, change in taste, seizures; one patient with schizoaffective disorder, which presumably existed prior to initiating therapy with sibutramine after treatment developed acute psychosis.

Cardiovascular system: tachycardia, palpitations, increased blood pressure, vasodilation (flushing with a sensation of heat), exacerbation of hemorrhoids; in some cases - a more pronounced increase in blood pressure and heart rate acceleration.

Urinary system: in rare cases - acute interstitial nephritis, mesangiocapillary glomerulonephritis.

Blood coagulation system: thrombocytopenia, Henoch-Schonlein purpura.

Most often side effects occur early in therapy (the first 4 weeks), their severity and frequency of occurrence over time are weaken.

Lesfat contraindications

Organic cause of obesity, well-known and established severe eating disorders (anorexia nervosa or bulimia nervosa), mental illness, Tourette syndrome, IBS, chronic heart failure in the stage of decompensation, congenital heart disease, occlusive peripheral artery disease, tachycardia, arrhythmias, cerebrovascular accident (including transient), uncontrolled hypertension (BP is more than 145/90 mm Hg), hyperthyroidism, severe renal dysfunction, severe hepatic dysfunction, benign prostatic hyperplasia with the formation of residual urine, pheochromocytoma, glaucoma, established pharmaceutical drug and alcohol abuse, pregnancy, lactation (breastfeeding), simultaneous taking or up to 2 weeks after discontinuation of MAO inhibitors or other drugs that have a dampening effect on the central nervous system (antidepressants, antipsychotics, tryptophan), or other medicines for weight loss, increased sensitivity to sibutramine.


Using during pregnancy and breastfeeding

Lesfat is contraindicated during pregnancy and lactation.

Women of childbearing age in the period of treatment should apply adequate methods of contraception.

Category of the fetus by FDA - C.

Special instructions

Use Lesfat only in cases where all activities are ineffective weight loss (when weight loss is less than 5 kg within 3 months).

Treatment should only be undertaken within the framework of the treatment of weight loss under medical supervision, which has practical experience in the treatment of obesity. Combined therapy includes both changes in diet and lifestyle and increased physical activity.

With caution use Lesfat in combination with drugs that increase the range of QT, in patients with hypokalemia and hypomagnesemia, epilepsy, impaired liver function with mild to moderate severity, with impaired renal function and mild to moderate severity, in patients with motor tics or family history of vocalism, simultaneously with drugs that increase blood pressure and heart rate (including medications used for coughs, colds and allergies).

Do not use in persons over 65 years due to lack of sufficient clinical experience with sibutramine in geriatrics.

Reactions to the cancellation of sibutramine (headache, increased appetite) are rare.

During the period of treatment you should not drink alcohol because of the need to diet.

Should not be used in children and adolescents under the age of 18 years due to lack of sufficient clinical experience with this category of patients.

There is currently no established effect on the ability of Lesfat to employment in potentially hazardous activities.

Lesfat drug interactions

When this drug applied simultaneously with:

- drugs inhibiting isoenzyme CYP3A4 increased plasma concentrations of metabolites of sibutramine, slightly increased the interval of QT.

- rifampin, phenytoin, carbamazepine, phenobarbital, dexamethasone, macrolide antibiotics may accelerate the metabolism of this medication.

- selective serotonin reuptake inhibitors (citalopram, fluoxetine, paroxetine, sertraline), agonist 5-HT1-receptors, derivatives of ergot alkaloids, opioids, centrally acting antitussives increases the risk of serotonin syndrome.

Lesfat in case of emergency / overdose

Symptoms: increased severity of side effects, most often - tachycardia, increased blood pressure, headache and dizziness.

Treatment: taking activated charcoal, symptomatic therapy, monitoring of vital functions, if an increase in blood pressure and tachycardia - a prescription of beta-blockers.


Lesfat pharmaceutical active ingredients containing related brand and generic drugs:

Active ingredient is the part of the drug or medicine which is biologically active. This portion of the drug is responsible for the main action of the drug which is intended to cure or reduce the symptom or disease. The other portions of the drug which are inactive are called excipients; there role is to act as vehicle or binder. In contrast to active ingredient, the inactive ingredient's role is not significant in the cure or treatment of the disease. There can be one or more active ingredients in a drug.

Lesfat available forms, composition, doses:

Form of the medicine is the form in which the medicine is marketed in the market, for example, a medicine X can be in the form of capsule or the form of chewable tablet or the form of tablet. Sometimes same medicine can be available as injection form. Each medicine cannot be in all forms but can be marketed in 1, 2, or 3 forms which the pharmaceutical company decided based on various background research results.
Composition is the list of ingredients which combinedly form a medicine. Both active ingredients and inactive ingredients form the composition. The active ingredient gives the desired therapeutic effect whereas the inactive ingredient helps in making the medicine stable.
Doses are various strengths of the medicine like 10mg, 20mg, 30mg and so on. Each medicine comes in various doses which is decided by the manufacturer, that is, pharmaceutical company. The dose is decided on the severity of the symptom or disease.

Lesfat destination | category:

Destination is defined as the organism to which the drug or medicine is targeted. For most of the drugs what we discuss, human is the drug destination.
Drug category can be defined as major classification of the drug. For example, an antihistaminic or an antipyretic or anti anginal or pain killer, anti-inflammatory or so.

Lesfat Anatomical Therapeutic Chemical codes:

A medicine is classified depending on the organ or system it acts [Anatomical], based on what result it gives on what disease, symptom [Therapeutical], based on chemical composition [Chemical]. It is called as ATC code. The code is based on Active ingredients of the medicine. A medicine can have different codes as sometimes it acts on different organs for different indications. Same way, different brands with same active ingredients and same indications can have same ATC code.

Lesfat pharmaceutical companies:

Pharmaceutical companies are drug manufacturing companies that help in complete development of the drug from the background research to formation, clinical trials, release of the drug into the market and marketing of the drug.
Researchers are the persons who are responsible for the scientific research and is responsible for all the background clinical trials that resulted in the development of the drug.



  1. Dailymed."SIBUTRAMINE HYDROCHLORIDE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
  2. "sibutramine". https://pubchem.ncbi.nlm.nih.gov/co... (accessed August 28, 2018).
  3. "sibutramine". http://www.drugbank.ca/drugs/DB0110... (accessed August 28, 2018).

Frequently asked Questions

Can i drive or operate heavy machine after consuming Lesfat?

Depending on the reaction of the Lesfat after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Lesfat not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.

Is Lesfat addictive or habit forming?

Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.

Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.



sdrugs.com conducted a study on Lesfat, and the result of the survey is set out below. It is noteworthy that the product of the survey is based on the perception and impressions of the visitors of the website as well as the views of Lesfat consumers. We, as a result of this, advice that you do not base your therapeutic or medical decisions on this result, but rather consult your certified medical experts for their recommendations.

Visitor reports

Visitor reported useful

No survey data has been collected yet

Visitor reported side effects

No survey data has been collected yet

Visitor reported price estimates

No survey data has been collected yet

Visitor reported frequency of use

No survey data has been collected yet

Visitor reported doses

No survey data has been collected yet

Visitor reported time for results

No survey data has been collected yet

Visitor reported administration

No survey data has been collected yet

Visitor reported age

No survey data has been collected yet

Visitor reviews

There are no reviews yet. Be the first to write one!

Your name: 
Spam protection:  < Type 18 here

The information was verified by Dr. Rachana Salvi, MD Pharmacology

© 2002 - 2022 "sdrugs.com". All Rights Reserved